OFSEP High Definition Cohort

NCT ID: NCT03603457

Last Updated: 2024-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

2842 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-10

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For neurologists and patients, it appears that one major unmet need, beside of course a cure to multiple sclerosis (MS), is to better appreciate the causal factors of disease progression, and even to obtain reliable predictive tools that could apply on the individual level and at different key moments in the disease course.

The overarching objective of the OFSEP-HD cohort is to determine prognostic factors of the evolution of disability in MS in real life, looking at disease characteristics, care practices potentially modifying the evolution of the disease since MS clinical onset and along specific post-onset landmarks. This general framework leads to study 3 specific research objectives:

1. To identify determinants (socio-demographic characteristics, clinical characteristics, health related quality of life (QoL), changes in classification, and biomarkers) for the progression of MS disease and its consequences;
2. To study the effectiveness of treatments in real life;
3. To merge both determinants and treatments for creating patient-centered prognostic tools for identifying specific subgroups of patients and helping making decision to start, maintain or adapt care management.

To achieve these objectives, the OFSEP (The French multiple sclerosis registry) infrastructure, managed under a quality insurance system, offers a unique opportunity for the first time in France to create a large cohort of MS cases, providing high-definition and sequential multimodal data.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of multiple sclerosis according to the most recent criteria at entry into the HD cohort
* Followed in one MS Clinical Reference Centre (CRC SEP)
* Newly diagnosed after the study start or
* If MS onset occurred before study start, regular follow-up in a CRC SEP
* Irreversible disability ≤ 7.0 (permanent use of a wheelchair) on EDSS at inclusion in the study


* Inability to answer questionnaires
* Pregnant women at the time of inclusion
Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

EDMUS Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Besançon

Besançon, , France

Site Status

CHU de Bordeaux

Bordeaux, , France

Site Status

CHU de Caen

Caen, , France

Site Status

CHU de Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

CHU de Créteil

Créteil, , France

Site Status

CHU de Dijon

Dijon, , France

Site Status

CHU de Grenoble

Grenoble, , France

Site Status

CHU de Lille

Lille, , France

Site Status

CHU de Limoges

Limoges, , France

Site Status

CHU de Lyon

Lyon, , France

Site Status

CHU de Montpellier

Montpellier, , France

Site Status

CHU de Nancy

Nancy, , France

Site Status

CHU de Nantes

Nantes, , France

Site Status

CHU de Nice

Nice, , France

Site Status

CHU de Nîmes

Nîmes, , France

Site Status

CHU Pitié-Salpétrière

Paris, , France

Site Status

CHU Saint-Antoine

Paris, , France

Site Status

Fondation Rothschild

Paris, , France

Site Status

CHI de Poissy-Saint-Germain-en-Laye

Poissy, , France

Site Status

CHU de Poitiers

Poitiers, , France

Site Status

CHU de Rennes

Rennes, , France

Site Status

CHU de Strasbourg

Strasbourg, , France

Site Status

CHU de Toulouse

Toulouse, , France

Site Status

CHU de Tours

Tours, , France

Site Status

CHU de Fort-de-France

Fort-de-France, , Martinique

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Martinique

References

Explore related publications, articles, or registry entries linked to this study.

Guillemin F, Casey R, Epstein J, Foucher Y, Laplaud D, Achit H, Rollot F, Leray E, Vukusic S; OFSEP-HD investigators. Prognostic factors of disability progression in multiple sclerosis in real life: the OFSEP-high definition (OFSEP-HD) prospective cohort in France. BMJ Open. 2025 Apr 7;15(4):e094688. doi: 10.1136/bmjopen-2024-094688.

Reference Type DERIVED
PMID: 40194873 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.